Detection of genetic modification factors for breast cancer

Australian researchers have discovered a gene-altering factor, which may open up new treatments for breast cancer patients.

This factor is the molecule ELF5, which allows doctors to transform cancer cells, making treatments such as anti-estrogen resistance more effective.

The findings of experts from the Garvan Institute of Medical Research in Sydney show that the ELF5 molecule can cause gene cells to be activated or stopped working.

Thanks to the control of these molecules, breast cancer cell sensitivity to female hormonal stimulation therapy is significantly increased.

Professor Chris Ormandy said: "ELF5 molecules determine whether cancer cells respond to female hormone stimulating therapy."

This finding has for the first time demonstrated the interaction between ELF5 molecules and breast cancer. Earlier, the molecule was discovered by Professor Ormandy's team in all breast cancer cells since 1999.

By 2008, the same group also proved that ELF5 stimulated lactation in women.

The discovery is expected to open up the prospect of modifying a cure for cancer cells. Patients with breast cancer can also avoid the risk of using other toxic treatments such as chemotherapy.

Breast cancer is the most common cancer, and the second leading cause of death for women.

In 2008, Australia had 13,600 breast cancer patients and after 5 years of treatment, the survival rate was 89%.